Video

Dr. Smith on the Development of Active Therapeutic Combinations in Acute Myeloid Leukemia

Catherine Smith, MD, assistant professor, Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, discusses developing active therapeutic combinations for the treatment of patients with acute myeloid leukemia

Catherine Smith, MD, assistant professor, Division of Hematology/Oncology, Department of Medicine, University of California San Francisco Helen Diller Comprehensive Cancer Center, discusses developing active therapeutic combinations for the treatment of patients with acute myeloid leukemia (AML).

At the 2017 ASH Annual Meeting, researchers discussed that clinical trials have been focused on developing active therapeutic combinations. Smith cites the benefit of such an approach in the recent FDA approval and application of midostaurin (Rydapt), an inactive single agent, in combination with chemotherapy. This resulted in an increase in overall survival (OS) in a randomized upfront trial compared to chemotherapy alone, demonstrating a 7% absolute benefit in 4-year OS.

Drugs that may not be ideal alone, when combined with the right agents, may be able to produce better outcomes. Ongoing trials of these more active second-generation FLT3 inhibitors are currently accruing in the upfront setting and the relapsed/refractory setting. These include upfront combinations with gilteritinib, quizartinib, induction chemotherapy, and hypomethylating agents.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Jun 18th 2025 - Jun 19th 2026

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity